Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. May 28, 2006; 12(20): 3180-3185
Published online May 28, 2006. doi: 10.3748/wjg.v12.i20.3180
Published online May 28, 2006. doi: 10.3748/wjg.v12.i20.3180
Tumor | Hormone produced | Percent malignant | Clinical features | 5 yr survival | Localization | Treatment |
Insulinoma | Insulin proinsulin | 10% | Hypoglycemia, neuroglycopenic symptoms | 97% | EUS, intraoperative ultrasound | Surgical resection, chemotherapy, dextrose |
Gastrinoma | Gastrin | 60%-90% | Peptic ulcer disease, diarrhea | 60%-70% | SRS, SPECT, EUS | Surgical resection, PPI, somatostatin |
Glucagonoma | Glucagon | 50%-90% | Necrolytic migratory erythema, diabetes, DVT, depression | 50%-60% | CT w/contrast, EUS | Surgical resection, nutritional support, somatostatin, chemotherapy, insulin |
VIPoma | Vasoactive intestinal peptide | 40%-70% | Secretory diarrhea, hypokalemia, achlorhydria | 50% | CT Scan, SRS | Somatostatin, correction ofelectrolytes, hydration, surgical resection |
Somatostatinoma | Somatostatin | 70%-80% | DM, cholelithiasis, steatorrhea | 40% | CT, EUS, SRS | Surgical resection chemotherapy, somatostatin |
Non-functional tumors | Pancreatic polypeptide | 60%-80% | Abdominal pain, weight loss, jaundice | 50% | CT, MRI | Surgical resection |
- Citation: Mulkeen AL, Yoo PS, Cha C. Less common neoplasms of the pancreas. World J Gastroenterol 2006; 12(20): 3180-3185
- URL: https://www.wjgnet.com/1007-9327/full/v12/i20/3180.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i20.3180